Search

Displaying all 3 results
  1. Pathway

    Dasatinib Inhibition of BCR-ABL

    smpdb.ca/view/SMP0123165
    Drug action

    Dasatinib is able to bind ABL with greater affinity than Imatinib (25-55 times more potent). It is therefore administered to patients with Imatinib resistance. … Dasatinib is a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia (CML), a cancer characterized by increased and unregulated growth of white blood cells in the bone marrow and the accumulation

    Drugs: Bafetinib
  2. Pathway

    Dasatinib Inhibition of BCR-ABL Action Pathway

    smpdb.ca/view/SMP0031696
    Drug action

    Notably, Dasatinib is ineffective against the T315I mutation in BCR-ABL, and further research is necessary. … Dasatinib is able to bind ABL with greater affinity than Imatinib, partly owing to its ability to recognize multiple states of the enzyme.

    Drugs: Dasatinib
  3. Pathway

    Bosutinib Inhibition of BCR-ABL Action Pathway

    smpdb.ca/view/SMP0031698
    Drug action

    Bosutinib may have a safer toxicity profile than both Imatinib and Dasatinib because it does not significantly inhibit the receptors KIT and PDGFR.

    Drugs: Bosutinib